Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Show more
Location: 100 Cambridgepark Drive, Cambridge, MA, 02140, United States | Website: https://www.vorbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
312.4M
52 Wk Range
$0.13 - $3.29
Previous Close
$2.31
Open
$2.30
Volume
16,061,699
Day Range
$2.30 - $2.84
Enterprise Value
173.2M
Cash
60.04M
Avg Qtr Burn
-25.07M
Insider Ownership
31.89%
Institutional Own.
48.46%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VCAR33 (ALLO) Details Acute myeloid leukemia | Failed Discontinued | |
Trem-cel (VOR33) + VCAR33 Details Acute myeloid leukemia | Failed Discontinued | |
Trem-cel (VOR33) + Mylotarg (VBP101) Details Acute myeloid leukemia, Myelodysplastic syndrome | Failed Discontinued |